European expert panel recommends Hexvix

Despite considerable positive evidence, the use of Hexvix has historically differed widely from country to country and between clinics. European recommendations from a consensus group have now been published, which may make the use of Hexvix-guided fluorescence cystoscopy more unison in Europe.

A group of European experts have reviewed and discussed the evidence for fluorescence cystoscopy using hexaminolevulinate Hexvix. When the group met in 2009, the members noted the accumulation of a strong evidence base for Hexvix-guided Transurethral Resection of Bladder (TURB) and that the technique was in use, as an adjunct to white-light cystoscopy in bladder cancer diagnosis, in many countries across Europe.

Various guidelines have been produced across the continent, acknowledging the role of fluorescence cystoscopy in the diagnosis and follow up of bladder cancer. However, there is no European consensus on its specific applications. In their analysis, the panel members argue that appropriate use of the technique brings benefits to patients, and to the healthcare economy, and they support the use of Hexvix-guided fluorescence cystoscopy in a range of indications. "We hope that our statement will lead to improved care and better outcomes for patients, through more complete resection of tumors and improved follow up" said Professor J A Witjes, chair of the panel.

The European expert panel's recommendations are available to support urologists in the clinical practice of fluorescence cystoscopy in the diagnosis and follow up of bladder cancer patients.

More information on Photocure ASA's website